Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate from Astellas
Company expanding pipeline of novel treatments for cardiovascular disease CAMBRIDGE, MASS. – [April 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with […]
